To date, phase III studies (ROMANA1 and ROMANA 2) have demonstrated that pharmacotherapies with anamorelin (a ghrelin receptor agonist) significantly increased lean body mass in patients with non-small cell lung cancer who underwent chemotherapy [41]. This evidence concerns the gene GHSR and non-small cell lung carcinoma.